A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Antitumor Activity of Gefitinib in Malignant Rhabdoid Tumor Cells In vitro and In vivo
Clinical Cancer Research
Purpose: Malignant rhabdoid tumor (MRT) is a rare and highly aggressive neoplasm of young children. Current treatments have had only limited success. Epidermal growth factor receptor (EGFR) was found recently to be expressed on MRT cell lines. Gefitinib (trade name Iressa) is an oral and selective EGFR-tyrosine kinase inhibitor and has been demonstrated to be effective in inhibiting the proliferation of cancer cells in vivo as well as in clinical trials. This encouraged us to examine thedoi:10.1158/1078-0432.ccr-04-0192 pmid:15355927 fatcat:4k5fvhcgpvetviiqrzlvhwshz4